Generalized anxiety and panic disorder

As per the insights shared in the American Family Physician journal, individuals struggling with anxiety disorders exhibit a higher likelihood of concurrent chronic medical conditions, presenting a twofold increased tendency toward somatic symptoms compared to unaffected patients. The symptomatic manifestations of Generalized Anxiety Disorder (GAD) and Panic Disorder (PD) may mimic various medical conditions, including hyperthyroidism, arrhythmias, asthma, chronic obstructive pulmonary disease, and certain medication-related scenarios such as use or withdrawal.
The etiology of anxiety disorders is intricate, encompassing psychological, biological, environmental, and genetic dimensions. These diverse factors contribute to the multifaceted origins of anxiety disorders. The spectrum of available treatments primarily falls within two categories: pharmacotherapy and psychotherapy. Cognitive Behavior Therapy (CBT) emerges as the most efficacious and extensively studied form of psychotherapeutic intervention.
Within the realm of pharmacotherapy, antidepressants take precedence, with Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) standing out as first-line therapeutic choices. It is recommended to sustain antidepressant use for a duration of six to 12 months to minimize the risk of relapse. Contrary to common assumptions, Benzodiazepines do not surpass antidepressants in effectiveness for anxiety disorder treatment and are discouraged as a first-line therapy. This nuanced approach aligns with the latest evidence-based practices in the management of anxiety disorders.